Pre-made Valanafusp benchmark antibody ( Whole mAb Fusion, anti-INSR therapeutic antibody, Anti-CD220/HHF5 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Valanafusp biosimilar, Whole mAb Fusion, Anti-INSR Antibody: Anti-CD220/HHF5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Valanafusp alpha is a BBB-penetrating form of IDUA, and is designed to deliver the IDUA enzyme to brain cells to reverse the accumulation of heparan sulfate (HS) GAGs and lysosomal inclusions. The primary therapeutic goal of valanafusp alpha therapy is stabilization of cognitive decline in severe MPSI.
| Products Name (INN Index) | Pre-Made Valanafusp biosimilar, Whole mAb Fusion, Anti-INSR Antibody: Anti-CD220/HHF5 therapeutic antibody |
|---|---|
| INN Name | Valanafusp |
| Target | INSR |
| Format | Whole mAb Fusion |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 5kqv:PQ:CD/4zxb:CD |
| 95-98% SI Structure | 3loh:CD/2dtg:CD/3w14:CD:PQ |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | ArmaGen Technologies |
| Conditions Approved | NA |
| Conditions Active | Mucopolysaccharidosis I |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | INSR |
| Package |
